OBJECTIVES: To characterize gender and race & ethnicity of chronic kidney disease (CKD) patients by estimated glomerular filtration rate (eGFR) status using US claims linked with lab data.

METHODS: The analysis used the US-claims-based dataset, the Komodo Healthcare Map, consisting of 330M patient lives linked with Komodo Lab Results to derive eGFR lab data. CKD patients were defined as having a claim by ICD10CM code between 1/1/2021 and 12/31/2022 and being payer-complete, closed patients (Mx and Rx) during this period. 5 stages of CKD by eGFR defined by the National Kidney Foundation (NKF) were observed. Distribution of patients for each stage was reported by gender and race & ethnicity.

RESULTS: Of the patients identified with closed Komodo claims and eGFR lab values, 69,092 (12%) were stage 1 (eGFR 90-150), 167,684 (29%) were stage 2 (eGFR 60-89), 276,254 (47%) were stage 3 (eGFR 30-59), 49,495 (8%) were stage 4 (eGFR 15-29), 19,719 (3%) were stage 5, and 1,506 (0.3%) had hyperfiltration (eGFR >150). For patients with stage 5 eGFR levels (eGFR <15), 9,388 (48%) of patients were female and 10,331 (52%) were male with race and ethnicity breakdown was 7,507 patients were White (43%), 5,054 patients were Black (29%), 1,076 patients were Asian (6%), 3,303 patients were Hispanic or Latino (19%), and 541 patients were other (3%).

CONCLUSIONS: CKD-diagnosed patients in payer-complete/closed claims data can be augmented with linked eGFR values to understand kidney disease patients by stage to further insights in CKD.